Payment overview · 2025
General Payments
$626.47
34 reported records · 12 companies
Healthcare provider profile · identity verified
Jon O Sides, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BURLINGTON, KS · NPI 1912901885
Verified facts
What the public records show
CMS Open Payments records show Jon O Sides, M.D. received $626.47 in general payments during 2025 across 34 reported records.
Otsuka America Pharmaceutical, Inc. accounted for 19.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $123.44 | 19.7% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $81.22 | 13.0% | 4 | 2025 |
| Verona Pharma, Inc. | Unresolved — no canonical attribution shown | $75.25 | 12.0% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.56 | 10.5% | 3 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $61.11 | 9.8% | 4 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $45.81 | 7.3% | 2 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $44.96 | 7.2% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $34.48 | 5.5% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $33.84 | 5.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $28.22 | 4.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $18.73 | 3.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $13.85 | 2.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $626.47 | 34 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $157.92 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $81.22 | 4 | 2025 |
Source payment records
|
|||||
| Ohtuvayre Normalized: ohtuvayre |
Drug | Verona Pharma, Inc. | $75.25 | 4 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $65.56 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $65.56 | 3 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $61.11 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $52.97 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $47.49 | 2 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $45.81 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $28.22 | 2 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $23.69 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.27 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $18.86 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $18.73 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.98 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.85 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
32 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 21 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Pantoprazole Sodium | Pantoprazole Sodium | 496 | 101 |
| Lisinopril | Lisinopril | 396 | 82 |
| Losartan Potassium | Losartan Potassium | 366 | 67 |
| Amlodipine Besylate | Amlodipine Besylate | 331 | 61 |
| Levothyroxine Sodium | Levothyroxine Sodium | 309 | 65 |
| Simvastatin | Simvastatin | 267 | 65 |
| Atorvastatin Calcium | Atorvastatin Calcium | 258 | 60 |
| Sertraline Hcl | Sertraline Hcl | 200 | 39 |
| Hydrochlorothiazide | Hydrochlorothiazide | 187 | 42 |
| Metoprolol Tartrate | Metoprolol Tartrate | 154 | 37 |
| Metformin Hcl | Metformin Hcl | 153 | 39 |
| Meloxicam | Meloxicam | 152 | 36 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 145 | 41 |
| Furosemide | Furosemide | 138 | 32 |
| Carvedilol | Carvedilol | 136 | 28 |
| Omeprazole | Omeprazole | 133 | 34 |
| Alprazolam | Alprazolam | 123 | 41 |
| Gabapentin | Gabapentin | 123 | 28 |
| Clopidogrel | Clopidogrel Bisulfate | 118 | 23 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 116 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 116 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 112 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 25 |
| Allopurinol | Allopurinol | 111 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 110 | 24 |
| Potassium Chloride | Potassium Chloride | 108 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 104 | 24 |
| Eliquis | Apixaban | 92 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 86 | 26 |
| Prednisone | Prednisone | 82 | 55 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 19 |
| Montelukast Sodium | Montelukast Sodium | 75 | 20 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 71 | 17 |
| Celecoxib | Celecoxib | 70 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 68 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 66 | 25 |
| Tramadol Hcl | Tramadol Hcl | 60 | 18 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 58 | 17 |
| Pregabalin | Pregabalin | 57 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 56 | suppressed |
| Clonazepam | Clonazepam | 49 | 11 |
| Escitalopram Oxalate | Escitalopram Oxalate | 48 | 12 |
| Ozempic | Semaglutide | 47 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 45 | 11 |
| Myrbetriq | Mirabegron | 44 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 11 |
| Glimepiride | Glimepiride | 40 | suppressed |
| Estradiol | Estradiol | 39 | 11 |
| Temazepam | Temazepam | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 38 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 37 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 37 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Spironolactone | Spironolactone | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Atenolol | Atenolol | 35 | suppressed |
| Famotidine | Famotidine | 35 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 35 | suppressed |
| Xarelto | Rivaroxaban | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 27 |
| Levofloxacin | Levofloxacin | 32 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 32 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 32 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 32 | suppressed |
| Synthroid | Levothyroxine Sodium | 32 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 29 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Fentanyl | Fentanyl | 26 | suppressed |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 26 | 20 |
| Topiramate | Topiramate | 26 | suppressed |
| Fluconazole | Fluconazole | 25 | 19 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 24 | suppressed |
| Ezetimibe | Ezetimibe | 24 | suppressed |
| Movantik | Naloxegol Oxalate | 24 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 23 | 20 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 14 |
| Methocarbamol | Methocarbamol | 22 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Klor-Con M20 | Potassium Chloride | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Sucralfate | Sucralfate | 21 | suppressed |
| Glipizide | Glipizide | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 19 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Finasteride | Finasteride | 16 | suppressed |
| Methylprednisolone | Methylprednisolone | 16 | 15 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 15 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Azithromycin | Azithromycin | 14 | 14 |
| Buspirone Hcl | Buspirone Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 14 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 13 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 12 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Tradjenta | Linagliptin | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Naltrexone Hcl | Naltrexone Hcl | 11 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 11 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $626.47 · 34 records | Otsuka America Pharmaceutical, Inc. | ABRYSVO, Auvelity, CAPVAXIVE, COMIRNATY, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, Dexcom G6 Transmitter, EVENITY, Ohtuvayre, Ozempic, PREVNAR 20, PROLIA, QULIPTA, REXULTI, Rybelsus, The Cologuard Plus Collection Kit, UBRELVY, Wegovy, YUPELRI | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error